[1
]
From Fundacion INFANT (F.P.P.) and iTrials-Hospital Militar Central (G.P.M.), Buenos
Aires; State University of New York, Upstate Medical University, Syracuse (S.J.T.),
and Vaccine Research and Development, Pfizer, Pearl River (J.A., A.G., K.A.S., K.K.,
W.V.K., D.C., P.R.D., K.U.J., W.C.G.) - both in New York; Vaccine Research and Development,
Pfizer, Hurley, United Kingdom (N.K., S.L., R.B.); Vaccine Research and Development
(J.L.P., P.L.) and Worldwide Safety, Safety Surveillance and Risk Management (S.M.),
Pfizer, Collegeville, PA; Associação Obras Sociais Irmã Dulce and Oswaldo Cruz Foundation,
Bahia (E.D.M.), and Centro Paulista de Investigação Clinica, São Paulo (C.Z.) - both
in Brazil; Global Product Development, Pfizer, Peapack, NJ (S.R.); Cincinnati Children's
Hospital, Cincinnati (R.W.F.); Johns Hopkins Bloomberg School of Public Health, Baltimore
(L.L.H.); BioNTech, Mainz (ÖT., U.Ş.), and Medizentrum Essen Borbeck, Essen (A.S.)
- both in Germany; Tiervlei Trial Centre, Karl Bremer Hospital, Cape Town, South Africa
(H.N.); Hacettepe University, Ankara, Turkey (S.Ü.); and Worldwide Safety, Safety
Surveillance and Risk Management, Pfizer, Groton, CT (D.B.T.).